Clinical

Dataset Information

0

Study of Cetuximab, Oxaliplatin, 5-FU/LV Versus Oxaliplatin, 5-FU/LV in Patients With Previously Treated Metastatic, EGFR-Positive Colorectal Cancer

ABSTRACT: The purpose of this study is to compare overall survival in patients with previously-treated metastatic, epidermal growth factor receptor (EGFR)-positive colorectal cancer treated with oxaliplatin, 5-fluorouracil and leucovorin (FOLFOX4) and cetuximab with FOLFOX4 alone.

DISEASE(S): Colorectal Cancer,Colorectal Neoplasms

PROVIDER: 2009329 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

Json Xml

Similar Datasets

Unknown Sequential therapy of refractory metastatic pancreatic cancer with 5-FU/LV/irinotecan (FOLFIRI) vs. 5-FU/LV/oxaliplatin (OFF). The PANTHEON trial (AIO PAK 0116).
| S-EPMC11217046 | biostudies-literature
Unknown Quality-adjusted survival with combination nal-IRI+5-FU/LV vs 5-FU/LV alone in metastatic pancreatic cancer patients previously treated with gemcitabine-based therapy: a Q-TWiST analysis.
| S-EPMC5482729 | biostudies-literature
Unknown Immunologic and tumor responses of pegilodecakin with 5-FU/LV and oxaliplatin (FOLFOX) in pancreatic ductal adenocarcinoma (PDAC).
| S-EPMC8944136 | biostudies-literature
Unknown nal-IRI+5-FU/LV versus 5-FU/LV in post-gemcitabine metastatic pancreatic cancer: Randomized phase 2 trial in Japanese patients.
| S-EPMC7774735 | biostudies-literature
Unknown Validation of the 12-gene colon cancer recurrence score in NSABP C-07 as a predictor of recurrence in patients with stage II and III colon cancer treated with fluorouracil and leucovorin (FU/LV) and FU/LV plus oxaliplatin.
| S-EPMC3871512 | biostudies-literature
Clinical Study of Irinotecan and Cetuximab Versus Irinotecan as Second-Line Treatment in Patients With Metastatic, EGFR-Positive Colorectal Cancer
| 2009422 | ecrin-mdr-crc
Unknown Osimertinib: A Review in Previously Untreated, EGFR Mutation-Positive, Advanced NSCLC.
| S-EPMC8536603 | biostudies-literature
Unknown CF10/LV overcomes acquired resistance to 5-FU/LV in colorectal cancer cells through downregulation of the c-Myc/ABCB5 axis.
| S-EPMC12367397 | biostudies-literature
Genomics Gene expression analysis of previously treated hormone receptor-positive metastatic breast cancer
| PRJNA527860 | ENA
Transcriptomics Differential mRNA expression analysis of EGFR-TKI-sensitive cells vs. EGFR-TKI-resistant cells
2021-04-18 | GSE172002 | GEO